Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation

Digestive Diseases

Volumn 35, Issue 3, 2017, Pages 241-245

  Chiang, John Y L ^a   Pathak, Preeti ^a   Liu, Hailiang ^a   Donepudi, Ajay ^a   Ferrell, Jessica ^a   Boehme, Shannon ^a  

^a Northeastern Ohio Medical University   (United States)

Author keywords

Bile acid synthesis; Cholesterol 7a hydroxylase; Diabetes; Drug therapy; Non alcoholic fatty liver disease

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 15; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; BILE ACID SYNTHESIS; CYP7A1 GENE; CYP8B1 GENE; ENTEROHEPATIC CIRCULATION; FXR GENE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; LIPID METABOLISM; LIVER CANCER; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; HUMAN; INTESTINE; LIVER; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BILE ACIDS AND SALTS; HUMANS; INTESTINES; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85014703255     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000450981     Document Type: Article

References (35)

1. Li T, Chiang JY: Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66: 948-983.
2. Chiang JY: Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966.
3. Inagaki T, et al: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006; 103: 3920-3925.
4. Jones BV, et al: Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 2008; 105: 13580-13585.
5. Aron-Wisnewsky J, et al: Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19: 338-348.
6. Kakiyama G, et al: Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-955.
7. Joyce SA, Gahan CG: The gut microbiota and the metabolic health of the host. Curr Opin Gastroenterol 2014; 30: 120-7.
8. Ridlon JM, et al: Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332-338.
9. Chiang JY, Miller WF, Lin GM: Regulation of cholesterol 7 alpha-hydroxylase in the liver. Purification of cholesterol 7 alpha-hydroxylase and the immunochemical evidence for the induction of cholesterol 7 alpha-hydroxylase by cholestyramine and circadian rhythm. J Biol Chem 1990; 265: 3889-3897.
10. Ferrell JM, Chiang JY: Circadian rhythms in liver metabolism and disease. Acta Pharm Sin B 2015; 5: 113-122.
11. Galman C, Angelin B, Rudling M: Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 1445-1453.
12. Lundasen T, et al: Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-536.
13. Asher G, Schibler U: Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab 2011; 13: 125-137.
14. Vollmers C, et al: Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci U S A 2009; 106: 21453-21458.
15. Hatori M, et al: Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 2012; 15: 848-860.
16. Pathak P, Li T, Chiang JY: Retinoic acid-related orphan receptor α regulates diurnal rhythm and fasting induction of sterol 12α-hydroxylase in bile acid synthesis. J Biol Chem 2013; 288: 37154-37165.
17. Ferrell JM, Chiang JY: Short-term circadian disruption impairs bile acid and lipid homeostasis in mice. Cell Mol Gastroenterol Hepatol 2015; 1: 664-677.
18. Watanabe M, et al: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418.
19. Zhang Y, et al: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006-1011.
20. Prawitt J, et al: Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871.
21. Watanabe M, et al: Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011; 286: 26913-26920.
22. Li F, et al: Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4: 2384.
23. Jiang C, et al: Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125: 386-402.
24. Jiang C, et al: Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6: 10166.
25. Fang S, et al: Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21: 159-165.
26. Maruyama T, et al: Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-719.
27. Kawamata Y, et al: A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-9440.
28. Keitel V, et al: Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372: 78-84.
29. Keitel V, et al: The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007; 45: 695-704.
30. Katsuma S, Hirasawa A, Tsujimoto G: Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-390.
31. Thomas C, et al: TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177.
32. Mojsov S, et al: Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986; 261: 11880-11889.
33. Ding X, et al: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181.
34. Watanabe M, et al: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489.
35. Sayin SI, et al: Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-235